Suscribirse

ACELLULAR PERTUSSIS VACCINES - 06/09/11

Doi : 10.1016/S0031-3955(05)70209-1 
Michael D. Decker, MD, MPH a, Kathryn M. Edwards, MD b
a Departments of Preventive Medicine and Medicine (Infectious Diseases) (MDD) 
b Pediatrics (KME), Vanderbilt University School of Medicine, Nashville, Tennessee 

Resumen

Pertussis (whooping cough) is a bacterial respiratory infection caused by the gram-negative bacillus Bordetella pertussis. Its hallmark is a cough illness that lasts many weeks. A related organism, Bordetella parapertussis, can produce a less severe pertussis-like syndrome. Pertussis may occur at any age (infection of adolescents and adults is increasingly recognized) but is most severe in infants and young children. Infants are susceptible to pertussis within the first few weeks or months of life, when the risk for mortality from whooping cough is highest.

Pertussis is acquired through direct transmission from close respiratory contact and is highly contagious; as many as 90% of susceptible household contacts will acquire the disease. Before the routine use of whole-cell pertussis vaccine, virtually every child experienced pertussis infection; as many as 270,000 cases of pertussis were reported each year in the United States, with 10,000 deaths.15 With vaccination, the prevalence of pertussis declined to a nadir of 1010 reported cases in 197612 but has progressively increased since. The 7796 cases reported for 1996 was the highest total in more than 30 years. Currently, in countries such as the United States, in which pertussis vaccination is common, the age distribution of pertussis has changed markedly. The increase in pertussis has been greatest among older children and adults, probably reflecting waning vaccine-induced immunity. Because pertussis often is undiagnosed in adolescents and adults, the actual number of cases likely greatly exceeds the number reported. Worldwide, an estimated 40 million pertussis cases occurred in 1994, resulting in 5 million episodes of pneumonia, 360,000 deaths, and 50,000 neurologic complications (including permanent brain damage).25

The incubation period averages 9 or 10 days. Onset is gradual; an intermittent cough progresses to paroxysms and the characteristic whoop begins. The whoop is caused by forced inspiration through a narrowed glottis immediately following a paroxysm of a dozen or more rapid, short coughs without intervening inspiration. Cyanosis and vomiting may ensue, and these children often are left exhausted; unfortunately, several paroxysms may occur within a few minutes. Between paroxysms, these children may appear normal. Recovery is gradual. Minor complications include subconjunctival hemorrhages, epistaxis, edema of the face, and ulcer of the frenulum. Major complications include pneumonia, encephalopathy, and wasting.

El texto completo de este artículo está disponible en PDF.

Esquema


 Address reprint requests to Michael D. Decker, MD, MPH, Vanderbilt University School of Medicine, A-1116 Medical Center North, Nashville, TN 37232–2637, e-mail: michael.decker@mcmail.vanderbilt.edu


© 2000  W. B. Saunders Company. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 47 - N° 2

P. 309-335 - avril 2000 Regresar al número
Artículo precedente Artículo precedente
  • POLIOVIRUS VACCINES : Progress Toward Global Poliomyelitis Eradication and Changing Routine Immunization Recommendations in the United States
  • Roland W. Sutter, D. Rebecca Prevots, Stephen L. Cochi
| Artículo siguiente Artículo siguiente
  • UPDATE ON HAEMOPHILUS INFLUENZAE SEROTYPE b AND MENINGOCOCCAL VACCINES
  • Nancy E. Rosenstein, Bradley A. Perkins

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.